atacicept

Merck: Results of the ADDRESS II Phase IIb multicenter study on atacicept in patients with systemic lupus erythematosus

Data presented at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting (Abstract Number: 12L) DARMSTADT,…

7 years ago